10 June 2021 |

Sucrosomial® Iron: new clinical trial performed by Dr. Guillermo Bastida

immagine generica di laboratorio scientifico

A new clinical trial entitled “Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment” and performed by Dr. Guillermo Bastida as first author, of the Department of Gastroenterology of University and Polytechnic La Fe Hospital of Valencia (Spain), has recently been published online in the journal Nutrients (IF: 4.546).

The study was prospective, multicenter, observational and conducted in four centers in Spain and one in Portugal. It had the aim to evaluate tolerability and effectiveness of Sucrosomial® Iron (SI) in inflammatory bowel disease (IBD) patients with mild anemia that previously failed treatment with, or be intolerant to, other oral iron formulations.

Authors concluded suggesting Sucrosomial® Iron as a valid and effective option to correct hemoglobin levels in IBD patients. Results of this study confirmed that Sucrosomial® Iron is well tolerated in patients with IBD, even in those with previous intolerance or laking of response to conventional oral iron salts, reinforcing the evidence, already showed in other published clinical trials, of the usefulness of Sucrosomial® Iron in patients with IBD (inflammatory bowel disease).